Curated News
By: NewsRamp Editorial Staff
July 14, 2026

HeartBeam Patent Adds Acoustic Sensing to Credit Card-Sized ECG Device

Discuss on LinkedIn Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • HeartBeam's new patent strengthens its IP portfolio, giving it an edge in cardiac monitoring with multi-modal sensing.
  • The patent integrates acoustic sensing and impedance measurement into HeartBeam's credit card-sized ECG device for heart failure monitoring.
  • HeartBeam's portable device enables earlier detection of heart valve issues and fluid congestion, improving patient outcomes at home.
  • HeartBeam's device combines digital stethoscope and fluid detection in a cable-free, credit card-sized format for cardiac care.

Impact - Why it Matters

This patent matters because it brings advanced diagnostic capabilities—like detecting heart valve problems and fluid buildup—to a portable device patients can use at home. For the millions living with heart failure or structural heart disease, this could mean earlier warnings and fewer hospital visits, transforming how cardiac care is managed outside clinical settings.

Summary

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received a new U.S. patent that integrates acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. This innovation allows the device to function as a digital stethoscope and assess fluid accumulation in the chest without changing its existing form factor. The patent strengthens HeartBeam’s intellectual property portfolio, enabling earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. The company said the patent advances its strategy of developing a multi-modal ambulatory cardiac sensing platform and expands its global patent portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications and device hardware.

HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The Company holds over 20 issued patents related to technology enablement.

To view the full press release, visit https://ibn.fm/jgVf0. The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT. AINewsWire, a specialized communications platform focusing on AI advancements, also covered this news as part of its Dynamic Brand Portfolio @ IBN. HeartBeam’s Cleared Indications for Use are detailed at https://www.heartbeam.com/indications.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Patent Adds Acoustic Sensing to Credit Card-Sized ECG Device

blockchain registration record for this content.